Eli Lilly and Company has acquired Boston-based Akouos, Inc.
The transaction is valued at approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million.
Akouos, Inc. is a precision genetic medicine company that is developing a portfolio of adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.
Eli Lilly discovers, develops, manufactures and sells pharmaceutical products. Its products are sold in 125 countries.
According to the LevinPro HC database, this acquisition is the 113th Biotechnology deal of the year. This compares with 100 Biotechnology transactions from January 1, 2021, through October 21, 2021.
